Congress Presses FDA To Speak Up On OTC/Supplement Combo Products
This article was originally published in The Tan Sheet
Executive Summary
Congressional interest turns up the pressure on FDA to make a statement on Bayer Aspirin with Heart Advantage, and issue a definitive policy on any products that combine dietary supplement and OTC drug ingredients
You may also be interested in...
Bayer Reboots Heart Advantage With Promotion For Aspirin
Bayer is using the reformulation of its Bayer Heart Health Advantage cholesterol-lowering phytosterol supplement as an opportunity to cross-promote with its aspirin brand
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
FDA Commissioner Must Not Come From Agency, Stupak Advises Obama
Rep. Bart Stupak has called on the incoming administration to look outside FDA for the next commissioner - even to fill the post short-term on an acting basis